← Back to Patent Explorer
US5298599A Expired / Lapsed US ⏱️ 0.0 years remaining

Expression and purification of recombinant soluble tissue factor

Assignee: Oklahoma Medical Research Foundation
•
Filing: 1992-01-03
•
Granted: 1994-03-29
•
Expires: 2012-01-03
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method is disclosed to make any protein in a form that can be isolated rapidly from a solution using a specific monoclonal antibody designated "HPC-4". It has now been determined that it is possible to form a fusion protein of the epitope with a protein to be isolated, and isolate the protein using HPC-4-based affinity chromatography. In the preferred embodiment, a specific protease cleavage site is inserted between the epitope and the protein so that the epitope can be easily removed from the isolated protein. In an example, a functionally active soluble tissue factor including the twelve amino acid epitope recognized in combination with calcium by HPC-4 and a factor Xa cleavage site was expressed from a vector inserted into a procaryotic expression system. The recombinant tissue factor can be rapidly isolated in a single chromatographic step using the HPC-4 monoclonal antibody immobilized on a suitable substrate. Once isolated, the Protein C epitope is removed by cleavage with factor Xa, leaving the functionally active, soluble tissue factor.

Inventors

  • 👤 Alireza Rezaie
  • 👤 Charles T. Esmon
  • 👤 James H. Morrissey

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 10:14
CPC Classifications
C; C07; C07K; C07K1/00; C07K1/107; C07K14/00; C07K14/435; C07K14/745; C07K14/7455; C07K16/00; C07K16/40; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6464; C12Y; C12Y304/00; C12Y304/21; C12Y304/21069; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/86; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/034; C07K2319/50; G01N2333/00; G01N2333/435; G01N2333/745; G01N2333/90; G01N2333/914; G01N2333/948; G01N2333/95; G01N2333/964; G01N2333/96425; G01N2333/96427; G01N2333/9643; G01N2333/96433; G01N2333/96441; G01N2333/96447; G01N2405/00; G01N2405/04

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 59 words
A fusion protein comprising an epitope which is capable of binding in the presence of calcium to the monoclonal antibody designated as HPC-4 (ATCC No. HB 9892) and a protein to be isolated by binding of the fusion protein to HPC-4 antibody, wherein the epitope and the protein to be isolated are separated by a specific protease cleavage site.
Claim 2
Dependent Claim 59 words
A fusion protein comprising an epitope which is capable of binding in the presence of calcium to the monoclonal antibody designated as HPC-4 (ATCC No. HB 9892) and a protein to be isolated by binding of the fusion protein to HPC-4 antibody, wherein the epitope and the protein to be isolated are separated by a specific protease cleavage site.
Claim 3
Dependent Claim 31 words
The fusion protein of claim 1 wherein the epitope consists of the amino acid sequence E D Q V D P R L I D G K (SEQ ID NO: 1).
Claim 4
Dependent Claim 61 words
The fusion protein of claim 1 wherein the protease cleavage site is selected from the group consisting of amino acid sequences specifically cleaved by Factor Xa; Ile Glu Gly Arg (IEGR, SEQ ID NO; 6), enterokinase: Asp Asp Asp Asp Lys (DDDDK, SEQ ID NO: 7), and thrombin: Phe/Gly Pro Arg (F/GPR, SEQ ID NO: 8 and SEQ ID NO: 9).
Claim 5
Dependent Claim 36 words
The fusion protein of claim 1 wherein the protein to be isolated is selected from the group consisting of tissue factor and a protein corresponding to the fourth through sixth epidermal growth factor domains of thrombomodulin.
Claim 6
Dependent Claim 44 words
The fusion protein of claim 1 consisting essentially of the amino acid sequence E D Q V D P R L I D G K (SEQ ID NO: 1) at the N-terminus, an amino acid sequence specifically cleaved by factor Xa, and tissue factor.
Claim 7
Dependent Claim 17 words
The fusion protein of claim 5 wherein the tissue factor is the extracellular domain of tissue factor.

References Cited (Backward Citations)

US4506009A Cited
WO1988004692A1 Cited
US4851341A Cited
EP0278776A2 Cited
WO1988007543A1 Cited
WO1988009817A1 Cited
EP0296413A2 Cited
WO1990007524A1 Cited
US5147638A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-03-28 1997-09-27 1998-03-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-03-28 2001-09-27 2002-03-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-03-28 2005-09-27 2006-03-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag